Paul Tudor Jones Beam Therapeutics Inc. Transaction History
Tudor Investment Corp Et Al
- $25.1 Billion
- Q4 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 16,575 shares of BEAM stock, worth $367,799. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,575
Previous 32,817
49.49%
Holding current value
$367,799
Previous $804,000
48.88%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding BEAM
# of Institutions
252Shares Held
78.5MCall Options Held
304KPut Options Held
142K-
Farallon Capital Management LLC San Francisco, CA8.24MShares$183 Million1.09% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$169 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.62MShares$169 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl7.07MShares$157 Million1.53% of portfolio
-
Arch Venture Management, LLC Chicago, IL4.54MShares$101 Million70.85% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $1.56B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...